$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

$sls Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000139047817000036 Filed on May 10, 2017

Income Statement

Concept	2017 Q1	2016 Q1	2015 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.287M	$3.525M	$2.895M
YoY Change	-35.12%	14.19%	-18.27%
% of Gross Profit
Research & Development	$2.184M	$5.443M	$5.740M
YoY Change	-59.88%	-6.56%	-18.29%
% of Gross Profit
Depreciation & Amortization	$26.00K	$6.000K	-$520.0K
YoY Change	333.33%	-93.88%	333.33%
% of Gross Profit
Operating Expenses	$4.471M	$8.968M	$8.635M
YoY Change	-50.14%	0.63%	-18.28%
Operating Profit	-$5.088M	-$8.968M	-$8.635M
YoY Change	-43.26%	0.63%	-18.28%
Interest Expense	-$130.0K	-$3.960M	$1.980M
YoY Change	-96.72%	-525.81%	-69.25%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$170.0K	$307.0K
YoY Change	-100.0%	-47.04%	-104.97%
Pretax Income	-$4.600M	-$13.10M	-$6.350M
YoY Change	-64.89%	57.64%	79.89%
Income Tax
% Of Pretax Income
Net Earnings	-$4.601M	-$16.49M	-$18.03M
YoY Change	-72.1%	56.52%	192.01%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.45	-$1.84	-$0.11
Diluted Earnings Per Share	-$153.3M	-$1.649B	-$1.803B
COMMON SHARES
Basic Shares Outstanding	26.41M shares	8.969M shares	161.9M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q1	2016 Q1	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.60M	$34.70M	$34.80M
YoY Change	-20.46%	-34.4%	41.46%
Cash & Equivalents	$18.10M	$34.71M	$34.71M
Short-Term Investments
Other Short-Term Assets	$14.40M	$3.300M	$19.40M
YoY Change	336.36%	17.86%	870.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$42.05M	$37.95M	$54.19M
YoY Change	10.8%	-33.8%	89.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$173.0K	$299.0K	$288.0K
YoY Change	-42.14%	-43.37%	-51.1%
Goodwill	$5.898M	$5.898M	$5.898M
YoY Change	0.0%	-2.82%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$100.0K	$200.0K
YoY Change	0.0%	-98.78%	-97.44%
Total Long-Term Assets	$28.29M	$28.42M	$28.48M
YoY Change	-0.46%	-44.59%	-44.12%
TOTAL ASSETS
Total Short-Term Assets	$42.05M	$37.95M	$54.19M
Total Long-Term Assets	$28.29M	$28.42M	$28.48M
Total Assets	$70.33M	$66.37M	$82.67M
YoY Change	5.98%	-38.89%	4.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.163M	$1.019M	$1.238M
YoY Change	14.13%	-69.06%	-63.15%
Accrued Expenses	$3.189M	$4.042M	$7.329M
YoY Change	-21.1%	-66.73%	-52.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$12.60M	$3.740M	$4.166M
YoY Change	236.82%	-6.36%	0.07%
Total Short-Term Liabilities	$36.27M	$42.22M	$37.09M
YoY Change	-14.1%	24.31%	17.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$1.526M
YoY Change		-100.0%	-70.06%
Other Long-Term Liabilities	$1.200M	$6.300M	$6.600M
YoY Change	-80.95%	-10.0%	-4.35%
Total Long-Term Liabilities	$1.200M	$6.300M	$1.526M
YoY Change	-80.95%	78.27%	-70.06%
TOTAL LIABILITIES
Total Short-Term Liabilities	$36.27M	$42.22M	$37.09M
Total Long-Term Liabilities	$1.200M	$6.300M	$1.526M
Total Liabilities	$43.14M	$53.95M	$50.25M
YoY Change	-20.04%	8.94%	3.33%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$345.7M	$312.1M	$296.0M
YoY Change	10.75%	8.02%	22.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.849M	$3.849M	$3.849M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	675.0K shares	675.0K shares	675.0K shares
Shareholders Equity	$27.19M	$12.41M	$32.42M
YoY Change
Total Liabilities & Shareholders Equity	$70.33M	$66.37M	$82.67M
YoY Change	5.98%	-38.89%	4.0%

Cashflow Statement

Concept	2017 Q1	2016 Q1	2015 Q3
OPERATING ACTIVITIES
Net Income	-$4.601M	-$16.49M	-$18.03M
YoY Change	-72.1%	56.52%	192.01%
Depreciation, Depletion And Amortization	$26.00K	$6.000K	-$520.0K
YoY Change	333.33%	-93.88%	333.33%
Cash From Operating Activities	-$3.803M	-$13.22M	-$9.460M
YoY Change	-71.22%	14.36%	-14.93%
INVESTING ACTIVITIES
Capital Expenditures		$6.000K	-$10.00K
YoY Change		-66.67%	-50.0%
Acquisitions
YoY Change
Other Investing Activities		-$1.050M	-$240.0K
YoY Change			-92.16%
Cash From Investing Activities	-$18.00K	-$1.056M	-$250.0K
YoY Change	-98.3%	103.86%	-91.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$15.52M	$20.19M
YoY Change	-23.11%	-52.07%
Debt Paid & Issued, Net	$0.00	$1.030M
YoY Change	-100.0%	8.76%
Cash From Financing Activities	$0.00	$19.25M	-760.0K
YoY Change	-100.0%	-53.37%	130.3%
NET CHANGE
Cash From Operating Activities	-$3.803M	-$13.22M	-9.460M
Cash From Investing Activities	-$18.00K	-$1.056M	-250.0K
Cash From Financing Activities	$0.00	$19.25M	-760.0K
Net Change In Cash	-$3.803M	$4.979M	-10.47M
YoY Change	-176.38%	-82.95%	-27.94%
FREE CASH FLOW
Cash From Operating Activities	-$3.803M	-$13.22M	-$9.460M
Capital Expenditures		$6.000K	-$10.00K
Free Cash Flow		-$13.22M	-$9.450M
YoY Change		14.24%	-14.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27600000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4979000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	9557000	USD
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001390478
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37435524	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	Galena Biopharma, Inc.
CY2017Q1	dei	Trading Symbol TradingSymbol	GALE
CY2016Q1	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	-3872000	USD
CY2017Q1	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	3892000	USD
CY2016Q1	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-170000	USD
CY2017Q1	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-113000	USD
CY2016Q1	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-170000	USD
CY2017Q1	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-113000	USD
CY2017Q1	gale	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-3892000	USD
CY2017Q1	gale	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	0	shares
CY2017Q1	gale	Classof Warrantor Right Expired ClassofWarrantorRightExpired	0	shares
CY2017Q1	gale	Classof Warrantor Right Granted ClassofWarrantorRightGranted	17000000	shares
CY2017Q1	gale	Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan	17000	shares
CY2016Q4	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	1095000	USD
CY2017Q1	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	1208000	USD
CY2016Q4	gale	Contract Research Payable ContractResearchPayable	3088000	USD
CY2017Q1	gale	Contract Research Payable ContractResearchPayable	2199000	USD
CY2017Q1	gale	Debt Instrument Covenant Liquidity Covenant DebtInstrumentCovenantLiquidityCovenant	13200000	USD
CY2017Q1	gale	Debt Instrument Redemption Principal Amount Redeemed DebtInstrumentRedemptionPrincipalAmountRedeemed	4450000	USD
CY2016Q4	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	-302932000	USD
CY2017Q1	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	-314650000	USD
CY2017Q1	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts	929000	USD
CY2017Q1	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition	P1Y7M13D
CY2017Q1	gale	Estimated Annualized Forfeiture Rate For Options Granted To Employees EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees	0.15
CY2017Q1	gale	Estimated Annualized Forfeiture Rate For Options Granted To Senior Management EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement	0.08
CY2014Q1	gale	Fair Value Of Parent Company Common Stock Issued In Exchange For Services FairValueOfParentCompanyCommonStockIssuedInExchangeForServices	0	USD
CY2016Q1	gale	Fair Value Of Parent Company Common Stock Issued In Exchange For Services FairValueOfParentCompanyCommonStockIssuedInExchangeForServices	41000	USD
CY2017Q1	gale	Fair Value Of Warrants Exercised FairValueOfWarrantsExercised	0	USD
CY2016Q1	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity	5590000	USD
CY2017Q1	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity	10357000	USD
CY2016Q4	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	1860000	USD
CY2017Q1	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	8325000	USD
CY2016Q4	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	1860000	USD
CY2017Q1	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	8325000	USD
CY2017Q1	gale	Fair Valueof Warrants Granted FairValueofWarrantsGranted	10357000	USD
CY2013Q2	gale	Fair Valueof Warrants Grantedper Share FairValueofWarrantsGrantedperShare	38.60
CY2016Q4	gale	Gale401rights GALE401rights	9255000	USD
CY2017Q1	gale	Gale401rights GALE401rights	9255000	USD
CY2016Q4	gale	In Process Research Development InProcessResearchDevelopment	12864000	USD
CY2017Q1	gale	In Process Research Development InProcessResearchDevelopment	12864000	USD
CY2016Q1	gale	Loss On Warrant Exchange LossOnWarrantExchange	3873000	USD
CY2017Q1	gale	Loss On Warrant Exchange LossOnWarrantExchange	-3892000	USD
CY2017Q1	gale	Options Reserved For Future Issuance Under Companies Incentive Plan OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan	483000	shares
CY2016Q1	gale	Paymentson Disposalof Productive Assets PaymentsonDisposalofProductiveAssets	1050000	USD
CY2016Q1	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise	46000	USD
CY2017Q1	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue	0	USD
CY2017Q1	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue		USD
CY2016Q4	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	100000	shares
CY2017Q1	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	15000	shares
CY2013Q2	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	9109	shares
CY2016Q2	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	50000	shares
CY2016Q3	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	50000	shares
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	840000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1163000	USD
CY2016Q1	us-gaap	Accretion Expense AccretionExpense	67000	USD
CY2017Q1	us-gaap	Accretion Expense AccretionExpense	650000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4292000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3189000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	229000	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	317000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	335436000	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	345689000	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	356000	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	228000	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	10357000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2389000	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20128000	shares
CY2016Q4	us-gaap	Assets Assets	65811000	USD
CY2017Q1	us-gaap	Assets Assets	70332000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	37499000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	42046000	USD
CY2016Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	813000	USD
CY2017Q1	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	367000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34709000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29730000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18083000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27640000	USD
CY2016Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-1050000	USD
CY2017Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
CY2016Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-3475000	USD
CY2017Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-5004000	USD
CY2016Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	79.40
CY2017Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	79.40
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	49.40
CY2016Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.60
CY2016Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	30.20
CY2016Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.60
CY2016Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2570000	shares
CY2017Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	19570000	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	20628000	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	162581753	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	215176965	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	161906753	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	214501965	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2016Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2017Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	4814000	USD
CY2017Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	4497466	shares
CY2016Q1	us-gaap	Costs And Expenses CostsAndExpenses	8968000	USD
CY2017Q1	us-gaap	Costs And Expenses CostsAndExpenses	5088000	USD
CY2016Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	17621702	USD
CY2017Q1	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	13171702	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1224672	USD
CY2017Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	575000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5661000	USD
CY2017Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5661000	USD
CY2016Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	96000	USD
CY2017Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	96000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.84
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	975000	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	673000	USD
CY2013Q2	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2016Q3	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2016	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2013Q2	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P7D
CY2016Q3	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5Y6M
CY2016	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5Y6M
CY2013Q2	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.7534
CY2016Q3	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	1.0663
CY2016	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.7713
CY2013Q2	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0120
CY2016Q3	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0135
CY2016	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0126
CY2016Q4	us-gaap	Goodwill Goodwill	5898000	USD
CY2017Q1	us-gaap	Goodwill Goodwill	5898000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-13102000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-2282000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-1.46
CY2017Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.09
CY2016Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-3391000	USD
CY2017Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-9436000	USD
CY2016Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.38
CY2017Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.36
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-578000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	323000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1250000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1103000	USD
CY2016Q1	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	84000	USD
CY2017Q1	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	-4432000	USD
CY2016Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-20000000	USD
CY2017Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	0	USD
CY2016Q1	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	-20000000	USD
CY2017Q1	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	0	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-418000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-132000	USD
CY2017Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	18000	USD
CY2016Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-91000	USD
CY2017Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-973000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	112000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	37154000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	43138000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	65811000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	70332000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	30398000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	36269000	USD
CY2016Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	6059000	USD
CY2017Q1	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	10045000	USD
CY2016Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	950000	USD
CY2017Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	950000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	16397000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	16397030	USD
CY2017Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	12597000	USD
CY2017Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	12597000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19251000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19979000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1056000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-18000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13216000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10404000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9741000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5400000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-16493000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-11718000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8968000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5088000	USD
CY2016Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-4134000	USD
CY2017Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	2806000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	581000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	449000	USD
CY2016Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	21000	USD
CY2017Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	42000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20189000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	15524000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	4450000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	78000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	5000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	199000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	173000	USD
CY2016Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1030000	USD
CY2017Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5443000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2362000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	18022000	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	13590000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3525000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2726000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	656000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	228000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7524
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0855
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0141
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0201
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	356000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	52.96
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	73000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	70000	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.20
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.45
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	561000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	558000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	41.50
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	37.68
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	32.59
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.75
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M17D
CY2017Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2017Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2017Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4814000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5000	USD
CY2016Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	41000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	15524000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	28657000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	27194000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28657000	USD
CY2017Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	27194000	USD
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2017Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2016Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
CY2017Q1	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8968616	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26406356	shares

Files In Submission

Name	View Source	Status
0001390478-17-000036-index-headers.html	Edgar Link	pending
0001390478-17-000036-index.html	Edgar Link	pending
0001390478-17-000036.txt	Edgar Link	pending
0001390478-17-000036-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gale-20170331.xml	Edgar Link	completed
gale-20170331.xsd	Edgar Link	pending
gale-20170331x10q.htm	Edgar Link	pending
gale-20170331xex103.htm	Edgar Link	pending
gale-20170331xex104.htm	Edgar Link	pending
gale-20170331xex105.htm	Edgar Link	pending
gale-20170331xex106.htm	Edgar Link	pending
gale-20170331_cal.xml	Edgar Link	unprocessable
gale-20170331_def.xml	Edgar Link	unprocessable
gale-20170331_lab.xml	Edgar Link	unprocessable
gale-20170331_pre.xml	Edgar Link	unprocessable
gale-2017x3031xex101.htm	Edgar Link	pending
gale20170331ex311.htm	Edgar Link	pending
gale20170331ex321.htm	Edgar Link	pending
logo-verticala16.jpg	Edgar Link	pending
logo-verticala17.jpg	Edgar Link	pending
pipelineq117.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

2017 Q1 Form 10-Q Financial Statement

#000139047817000036 Filed on May 10, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS SELLAS Life Sciences Group, Inc. Stock $sls

2017 Q1 Form 10-Q Financial Statement

#000139047817000036 Filed on May 10, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls